MedTrace Logo

PARP Inhibition for Gliomas (PI-4G or π4g)

NCT05297864 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

Conditions

Interventions

DRUG

Niraparib

The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.

Sponsors & Collaborators

Principal Investigators

  • James Battiste, MD · Stephenson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-09
Primary Completion
2023-11-14
Completion
2024-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05297864 on ClinicalTrials.gov